Abstract
Phosphatase and tensin homolog (PTEN) acts as a brake for the phosphatidylinositol 3-kinase–AKT–mTOR complex 1 (mTORC1) pathway, the deletion of which promotes potent central nervous system (CNS) axon regeneration. Previously, we demonstrated that AKT activation is sufficient to promote CNS axon regeneration to a lesser extent than PTEN deletion. It is still questionable whether AKT is entirely responsible for the regenerative effect of PTEN deletion on CNS axons. Here, we show that blocking AKT or its downstream effectors, mTORC1 and GSK3β, significantly reduces PTEN deletion-induced mouse optic nerve regeneration, indicating the necessary role of AKT-dependent signaling. However, AKT is only marginally activated in PTEN-null mice due to mTORC1-mediated feedback inhibition. That combining PTEN deletion with AKT overexpression or GSK3β deletion achieves significantly more potent axonal regeneration suggests an AKT-independent pathway for axon regeneration. Elucidating the AKT-independent pathway is required to develop effective strategies for CNS axon regeneration.
Introduction
Phosphatase and tensin homolog (PTEN) is a lipid phosphatase that acts as a brake for phosphatidylinositol 3-kinase (PI3K). Similar axon-regeneration phenotypes after PTEN deletion have been reported for mouse retinal ganglion cells (RGCs)1, cortical motor neurons2, drosophila sensory neurons3, and Caenorhabditis elegans motor neurons4, presumably through activating the PI3K pathway. The PI3K–AKT pathway is the central effector of multiple growth factors’ signaling to promote cell growth and survival5, mainly through the activation of mammalian target of rapamycin complex 1 (mTORC1), a master regulator of protein synthesis and cellular growth6,7. mTORC1-mediated activation of ribosomal protein S6 kinase 1 (S6K1) and inhibition of eukaryotic initiation factor 4E-binding proteins (4E-BPs) are critical for mRNA biogenesis, translation initiation, and elongation8.
AKT also phosphorylates and inhibits glycogen synthase kinase 3β (GSK3β), which is critical for neuronal polarization and axon branching, growth, and regeneration9,10. We have previously shown that S6K1 activation induces only very weak axon regeneration, whereas 4E-BP inhibition is necessary but not sufficient for axon regeneration11. Thus, in general, mTORC1 plays a necessary role in axon regeneration12. Interestingly, S6K1 also functions as a feedback inhibitor of PI3K signaling, which reduces AKT activation13,14. We found that a constitutive on S6K1 mutant inhibits AKT phosphorylation (pAKT) and decreases PTEN knockout (KO)-induced axon regeneration11, indicating the necessary role of AKT activation in axon regeneration. We further demonstrated that AKT activation induces central nervous system (CNS) axon regeneration through mTORC1 and GSK3β, two parallel and synergistical downstream effectors10.
It is still unknown whether AKT is the sole effector of PTEN KO for axon regeneration; it is only minimally activated in PTEN KO mice due to the feedback inhibition by mTORC1/S6K1. By exploiting RGCs and the crushed optic nerve (ON) as an in vivo axon injury model, we confirm the necessary role of AKT in PTEN deletion-induced axon regeneration, which acts through its downstream effectors mTORC1 and GSK3β. We also provide evidence that AKT-independent signaling is required to promote potent axon regeneration. Moreover, forced AKT activation or deletion of GSK3β further enhances PTEN deletion-induced axon regeneration, pointing toward more promising regeneration strategies based on targeting both AKT-dependent and -independent signals for CNS repair.
Results
AKT inhibition significantly reduces PTEN deletion-induced axon regeneration
AKT3 is the major AKT isoform in RGCs and the most potent for axon regeneration10. To definitively determine the role of AKT in PTEN deletion-induced axon regeneration, we deleted AKT3 in PTEN KO mice. We crossed PTEN-floxed mice with AKT3 KO mice to generate PTEN/AKT3 double KO (DKO) RGCs after adeno-associated virus 2 (AAV2)-Cre intravitreal injection. We performed ON crush in these mice 2 weeks after AAV2-Cre injection. RGC axons that regenerated through the lesion site were labeled anterogradely by the intravitreal injection of the tracer Alexa 488-conjugated cholera toxin β (CTB). The axons were imaged and quantified in ON longitudinal sections at 14 days post crush (dpc): there was significantly less axon regeneration than in PTEN single KO mice (Fig. 1). Other AKT isoforms (AKT1 and AKT2) may have redundant roles on axon. Therefore, we generated AAV2 vectors containing a U6 promoter-driven shRNA construct that targeted a common sequence of AKT1 and AKT2 and a GFP construct for monitoring shRNA expression. We confirmed the total AKT KO effect by in situ hybridization with probes targeting AKT1-3 in AKT3 KO mice injected with AAV-U6-AKT1/2 shRNA (Supplementary Fig. 1). AAV2-U6-AKT1,2 shRNA intravitreal injection also further decreased, but did not totally abolish, axon regeneration in PTEN/AKT3 DKO mice (Fig. 1). Interestingly, AKT3 KO alone did not affect PTEN deletion-induced RGC survival, but blocking all the three isoforms of AKT significantly reduced RGC survival in PTEN KO mice (Supplementary Fig. 2A, B), indicating the redundant roles of AKT isoforms in RGC survival. However, some axons regenerated even with all the three AKT isoforms removed, suggesting an AKT-independent pathway. Thus, our data indicate that the three AKT isoforms act as redundant AKT signals that contribute to the effect of PTEN KO on axon regeneration and RGC survival.
Marginal AKT activation after PTEN deletion in RGCs results in adequate mTORC1 activation for axon regeneration
Next, we examined AKT activation in whole mounts of PTEN KO RGCs. pAKT was only slightly increased, but mTORC1 was activated robustly, indicated by the significantly increased phosphorylation of ribosome protein S6 (pS6), which is a substrate of S6K1 and has often served as a marker for mTORC1 activation (Fig. 2). The low AKT activation was responsible for mTORC1 activation because blocking AKT by AKT3 deletion and AKT1/2 shRNA significantly decreased both pAKT and pS6 in PTEN KO mice (Fig. 2). To test whether mTORC1 limits AKT activation through feedback inhibition7,11, we targeted Rptor (regulatory associated protein of mTOR), which is unique to mTORC1 and the deletion of which blocks mTORC1 activity7,15. Destruction of mTORC1 by AAV2-Cre-mediated deletion of Rptor and Pten in Rptor/Pten double-floxed mice significantly decreased pS6 but increased pAKT (Fig. 2), indicating a feedback loop in PTEN KO RGCs. Thus, the balance between PTEN KO forward activation and mTORC1 feedback inhibition results in limited AKT activation but reasonable mTORC1 activation, which may be essential for axon regeneration. To confirm this notion, we performed an ON crush injury in Pten/Rptor DKO mice and, as expected, found that Rptor deletion (mTORC1 inhibition) significantly decreased PTEN KO-induced axon regeneration (Fig. 3). This result is consistent with our previous finding that mTORC1 is necessary for axon regeneration11,12. Taken together, these observations led us to conclude that PTEN deletion results in slight AKT activation, which activates mTORC1 adequately to allow axon regeneration.
AKT-induced GSK3β phosphorylation/inhibition is also necessary for PTEN deletion-induced axon regeneration
We have shown before that mTORC1 activation and GSK3β S9 phosphorylation/inhibition contribute synergistically to AKT-induced axon regeneration10. To further confirm the role of GSK3β S9 phosphorylation/inhibition in PTEN KO-induced axon regeneration, we prepared an AAV2-GSK3β-S9A mutant that cannot be phosphorylated by AKT and therefore cannot be inhibited after PTEN deletion. We then performed an ON crush injury in PTEN KO mice with GSK3β-S9A overexpression (constitutive on GSK3β) and found significantly decreased axon regeneration (Fig. 3). In addition, combining Rptor deletion and GSK3β-S9A overexpression further decreased, but did not totally abolish, PTEN KO-induced axon regeneration (Fig. 3), indicating the synergistic effects of these two parallel downstream effectors of AKT and also suggesting the possibility of AKT-independent signaling in PTEN deletion-induced axon regeneration. Unfortunately, because the phosphor-GSK3β-S9 antibody does not produce dependable immunostaining when the pGSK3β-S9 level is low, we detected hardly any increase of pGSK3β-S9 in Pten KO RGCs compared to wild-type (WT) RGCs (Fig. 2) and were unable to detect a further decrease with GSK3β-S9A overexpression. This result suggests, however, that the low activation of AKT in PTEN KO mice induces only a low level of pGSK3β-S9 and that this amount is necessary for axon regeneration. Surprisingly, neither mTORC1 inhibition nor GSK3β-S9A overexpression affects PTEN KO-induced RGC protection (Supplementary Fig. 2C, D), implying that other effectors downstream of AKT contribute to RGC survival. These results are additional evidence for the partial but essential role of AKT and its downstream effectors (mTORC1 and GSK3β) in PTEN KO-induced axon regeneration.
Robust AKT activation or GSK3β deletion promotes more potent axon regeneration in Pten KO mice
Since AKT is only marginally activated in PTEN KO mice (Fig. 2) and we have previously shown that sustained potent activation of AKT3 in RGCs by AAV2-myr-AKT3 injection promotes significant axon regeneration10, we used the same AAV vectors to overcome the feedback inhibition of mTORC1 and, therefore, to force AKT activation in PTEN KO mice. As expected, AAV2-myr-AKT3 intravitreal injection significantly increased the phosphorylation levels of AKT and GSK3β S9 (Supplementary Fig. 3) (please note that only overexpression of AKT can achieve this reliable pGSK3β S9 labeling) and resulted in significantly more and longer regenerating axons than PTEN KO alone (Fig. 4a, b). Similarly, AAV2-Cre-mediated Pten/Gsk3β DKO also resulted in more potent axon regeneration than PTEN KO alone (Fig. 4a, b). Fully activated AKT or the total deletion of GSK3β, therefore, acts synergistically with AKT-independent signaling downstream of PTEN deletion to promote CNS axon regeneration.
Discussion
The results of our present and earlier studies using genetic manipulations in RGCs specifically provide a molecular dissection of the PTEN–PI3K–AKT–mTORC1–GSK3β signaling pathway and definitively determine the linear and parallel signals that contribute to CNS axon regeneration (Fig. 4c). We have previously demonstrated that mTORC1 and its downstream effectors, S6K1 and 4E-BP, are necessary for PTEN KO-induced axon regeneration11,12. This conclusion led us to propose that a key proactive signal originating downstream from PTEN triggers the neuron intrinsic-growth machinery12. We later showed that AKT activation alone is sufficient to promote axon regeneration through the modulation of two parallel pathways, mTORC1 and GSK3β, and that the regeneration is less extensive than that of PTEN deletion10. Thus, AKT is a downstream effector of PTEN but cannot fully account for the effect of PTEN deletion on axon regeneration. The results of the present study confirm that AKT is only marginally activated after PTEN deletion due to mTORC1/S6K1-mediated feedback inhibition (Fig. 2), which is consistent with our previous observation that constitutive S6K1 activation decreases pAKT and axon regeneration in PTEN KO mice11. A similar effect has also been found in C. elegans16, and the inhibition of S6K1 has recently been shown to promote regeneration in mouse spinal cord17. We further demonstrated that the low AKT activation results in adequate, but not robust, mTORC1 activation and GSK3β inhibition, which are necessary for PTEN deletion-induced CNS axon regeneration. We also confirmed the functional redundancy of AKT isoforms in mediating PTEN effect, as in other systems18.
Clearly, however, these low levels of AKT activation and GSK3β inhibition are insufficient for axon regeneration. PTEN deletion must function through an AKT-independent pathway, which stimulates axon regeneration, but needs to cooperate with AKT-dependent signals to release the full potential of PTEN deletion. This uncharacterized pathway acts in parallel or by cross talk with the AKT-dependent pathway because potent AKT activation or total GSK3β inhibition further enhances regeneration in PTEN KO mice (Fig. 4c). Interestingly, AKT-independent GSK3β inhibition has been shown in peripheral axon regeneration19, and it will be interesting to determine whether the downstream effectors of GSK3β signaling comprise the nodal point that connects with PTEN deletion-induced AKT-independent signaling. Because the major cellular function of PTEN is to dephosphorylate PIP3 to PIP25, PTEN deletion will increase PIP3 and, therefore, activate PIP3-dependent signaling, including many AKT-independent pathways20. In addition, PTEN can dephosphorylate focal adhesion kinase (FAK) and Shc, and the deletion of PTEN activates FAK, RAS, and ERK21. Furthermore, PTEN is also present in the nucleus, where it is proposed to play a non-catalytic role in chromosomal instability and DNA repair22,23. Elucidation of these PTEN-dependent but AKT-independent pathways and the mechanisms by which they are cross regulated with the AKT-dependent pathway is likely to lead eventually to safe and effective regenerative strategies for CNS repair.
Methods and materials
Mice
Ptenflox/flox and Rptorflox/flox mice with C57BL/6 background and C57BL/6 WT mice were purchased from Jackson Laboratories (Bar Harbor, Maine). Gsk3bflox/flox mice with C57BL/6 background were originally developed by Dr. Jim Woodgett24,25 and were acquired from Dr. Thomas Force. AKT3 KO mice were acquired from the Dr. Morris Birnbaum lab26. Either sex was randomly used in experiments. All experimental procedures were performed in compliance with the animal protocols approved by the IACUC at Stanford University School of Medicine. For all surgical and treatment comparisons, control and treatment groups were prepared together in single cohorts, and the experiment was repeated at least twice.
Constructs
AAV-Myr-3HA-AKTs, AAV-3HA-GSK3β-S9A, and AAV-Cre have been described before10.
AAV production
The detailed procedure has been described previously11,27. Briefly, AAV plasmids containing the transgenes were co-transfected with pAAV2 (pACG2)-RC triple mutant (Y444, 500, 730F)28–30 and the pHelper plasmid (Stratagene) into HEK293T cells. Seveny-two hours after transfection, the cells were lysed to release the viral particles, which were precipitated by 40% polyethylene glycol and purified by cesium chloride density-gradient centrifugation. The fractions with refractive index from 1.370 to 1.374 were taken out for dialysis in a MWCO 7000 Slide-A-LYZER cassette (Pierce) overnight at 4 °C. The AAV titers that we used for this study were in the range of 1.5–2.5 × 1012 genome copies/ml, determined by real-time PCR.
Intravitreal injection and ON crush
Mice were anesthetized by xylazine and ketamine based on their body weight (0.01 mg xylazine/g + 0.08 mg ketamine/g). For each AAV intravitreal injection, a micropipette was inserted into the peripheral retina of 3-week-old mice just behind the ora serrata and advanced into the vitreous chamber so as to avoid damage to the lens. Approximately 2 µl of the vitreous was removed before injection of 2 µl AAV into the vitreous chamber. Roughly 3 × 109 vector genome/retina routinely achieves more than 80% RGC transduction, as assessed by Cre-dependent reporter mouse line11. ON crush was performed 2 weeks after AAV injection (5weeks old): the ON was exposed intraorbitally and crushed with a jeweler’s forceps (Dumont #5; Fine Science Tools, Foster City, CA, USA) for 5 s approximately 0.5 mm behind the eyeball. Care was taken not to damage the underlying ophthalmic artery. Eye ointment containing neomycin (Akorn, Somerset, NJ, USA) was applied to protect the cornea after surgery.
RGC axon anterograde tracing
Two microliters of CTB conjugated with fluorescence Alexa-488 (2 μg/μl; Invitrogen) was injected into the vitreous chamber 2 days before euthanizing the animals at 7 weeks old (2 weeks after ON crush) to label the regenerating axons in the ON. Animals were euthanized by CO2 and fixed by perfusion with 4% paraformaldehyde in cold phosphate-buffered saline (PBS). Eyes with the nerve segment still attached were dissected out and post-fixed in the same fixative for another 2 h at room temperature. Tissues were cryoprotected with increasing concentrations of sucrose (15–30%) and optimal cutting temperature compound (Tissue Tek). They were then snap frozen in dry ice, and serial longitudinal cross sections (8 µm) were cut and stored at −80 °C until processed.
Immunohistochemistry of flat-mount retina
Retinas were dissected out from 4% paraformaldehyde (PFA)-fixed eyes and washed extensively in PBS before blocking in staining buffer (10% normal goat serum and 2% Triton X-100 in PBS) for 30 min. Mouse or rabbit antibodies for neuronal class ß-III tubulin (clone Tuj1, 1:500; Covance), rat HA (clone 3F10, 1:200; Roche), phospho-S6-Ser240/244 (1:200, #5364; Cell Signaling), phospho-AKT-Ser473 (1:200, #4058; Cell Signaling), pan AKT (1:200, #2920; Cell Signaling), and phospho-GSK-3β (Ser9) (1:100, #9323; Cell Signaling) were diluted in the same staining buffer. RBPMS guinea pig antibody was made at ProSci, CA, according to publications31,32. Floating retinas were incubated with primary antibodies overnight at 4 °C and washed three times for 30 min each with PBS. Secondary antibodies (Cy2, Cy3, or Cy5 conjugated) were then applied (1:200; Jackson ImmunoResearch) and incubated for 1 h at room temperature. Retinas were again washed three times for 30 min each with PBS before a cover slip was attached with Fluoromount-G (SouthernBiotech).
Counting surviving RGCs and regenerating axons
For RGC counting, whole-mount retinas were immunostained with the Tuj1 antibody, and 6–9 fields were randomly sampled from the peripheral regions of each retina. All the Tuj1+ RGCs were counted from each field to generate the average surviving RGC number/retina. The percentage of RGC survival was calculated as the ratio of surviving RGC numbers in injured eyes to those in contralateral uninjured eyes. For axon counting, the number of CTB-labeled axons was quantified as described previously1,11,33. Briefly, we counted the fibers that crossed the perpendicular lines drawn on the ON sections distal to the crush site in increments of 250 µm till 1000 µm, and then every 500 µm till no fibers were visible. The width of the nerve (R) was measured at the point (d), at which the counts were taken, and used together with the thickness of the section (t = 8μm) to calculate the number of axons per µm2 area of the nerve. The formula used to calculate is ∑ad = πr2× (axon number)/(R × t). The total number of axons per section was then averaged over threesections per animal. All CTB signals that were in the range of intensity that was set from the lowest intensity to the maximum intensity after background subtraction were counted as individual fibers by Nikon NIS Element R4 software. The investigators who counted the cells or axons were blinded to the treatment of the samples.
Fluorescent in situ hybridization with retina cross sections
Adult mice were perfused with ice-cold 4% PFA/PBS, and the eyeballs were dissected out and fixed in 4% PFA/PBS at 4 °C overnight. The eyeballs were dehydrated with increasing concentrations of sucrose solution (15–30%) overnight before embedding in optimal cutting temperature compound on dry ice. Serial cross sections (12 µm) were cut with a Leica cryostat and collected on Superfrost Plus Slides. The sections were pretreated with protease and then subjected to in situ hybridization with RNAscope Multiplex Fluorescent Detection Reagents V2 according to the manufacturer’s instruction (Advanced Cell Diagnostics, Hayward, CA, USA). Briefly, the sections were hybridized with the probe solution, followed by amplification and probe detection using TSA plus fluorescein/cyanine 5 (PerkinElmer, San Jose, CA, USA). The sections were mounted with Fluoromount-G (SouthernBiotech, Birmingham, AL, USA). Images were captured by Zeiss LSM 880 confocal laser scanning microscope with 63 × /1.40 Oil DIC (Carl Zeiss Microscopy, Thornwood, NY, USA). RNAscope probes Mm-Akt1, Mm-Akt2, and Mm-Akt1 were purchased from ACD and targeted bases 1130–2560, 2618–3665, and 24–1138 of mouse Akt1, Akt2, and Akt3 mRNA (NCBI reference sequence: NM_009652.3, NM_007434.4, and NM_011785.3), respectively.
Statistical analyses
GraphPad Prism 6 was used to generate graphs and for statistical analyses. Data are presented as means ± s.e.m. One-way analysis of variance with post hoc test was used for multiple comparisons.
Supplementary information
Acknowledgements
We thank Drs. Alan Tessler, Hannah Webber, and Dakai Yang for critically reading the manuscript. We are grateful to Dr. Thomas Force and Dr. Morris Birnbaum for providing Gsk3b-floxed mice and Akt3 KO mice, respectively. Y.H. is supported by NIH grants EY024932, EY023295, and EY028106, RPB William & Mary Greve Special Scholar Award GFW9091, and Shriners Hospitals for Children research grant #85700. L.M. and L.Y. are supported by postdoctoral fellowships from Shriners Hospitals for Children. Portions of this work were supported by the NIH grant EY-25295 to Y.S. We are grateful for an unrestricted grant from Research to Prevent Blindness and NEI P30-026877 to the Department of Ophthalmology.
Authors' contributions
Y.H. and H.H. designed the experiments. H.H., L.M., L.Y., F.L., Q.W. and P.Z. performed the experiments and analyzed the data. Q.W. helped with AAV production and P.Z. performed in situ hybridization. Y.H., H.H., L.Y., Q.W. and Y.S. prepared the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
Edited by R. Franklin
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Haoliang Huang, Linqing Miao, Liu Yang
Supplementary information
Supplementary Information accompanies this paper at (10.1038/s41419-018-1289-z).
References
- 1.Park KK, et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science. 2008;322:963–966. doi: 10.1126/science.1161566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Liu K, et al. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat. Neurosci. 2010;13:1075–1081. doi: 10.1038/nn.2603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Song Y, et al. Genes Dev. 2012. Regeneration of Drosophila sensory neuron axons and dendrites is regulated by the Akt pathway involving Pten and microRNA bantam; pp. 1612–1625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Byrne AB, et al. Insulin/IGF1 signaling inhibits age-dependent axon regeneration. Neuron. 2014;81:561–573. doi: 10.1016/j.neuron.2013.11.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012;13:283–296. doi: 10.1038/nrm3330. [DOI] [PubMed] [Google Scholar]
- 6.Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274. doi: 10.1016/j.cell.2007.06.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293. doi: 10.1016/j.cell.2012.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–1945. doi: 10.1101/gad.1212704. [DOI] [PubMed] [Google Scholar]
- 9.Kim YT, Hur EM, Snider WD, Zhou FQ. Role of GSK3 signaling in neuronal morphogenesis. Front. Mol. Neurosci. 2011;4:48. doi: 10.3389/fnmol.2011.00048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Miao L, et al. mTORC1 is necessary but mTORC2 and GSK3beta are inhibitory for AKT3-induced axon regeneration in the central nervous system. eLife. 2016;5:e14908. doi: 10.7554/eLife.14908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Yang L, et al. The mTORC1 effectors S6K1 and 4E-BP play different roles in CNS axon regeneration. Nat. Commun. 2014;5:5416. doi: 10.1038/ncomms6416. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hu Y. The necessary role of mTORC1 in central nervous system axon regeneration. Neural Regen. Res. 2015;10:186–188. doi: 10.4103/1673-5374.152363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev. 2002;16:2627–2632. doi: 10.1101/gad.239102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Um SH, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–205. doi: 10.1038/nature02866. [DOI] [PubMed] [Google Scholar]
- 15.Guertin DA, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell. 2006;11:859–871. doi: 10.1016/j.devcel.2006.10.007. [DOI] [PubMed] [Google Scholar]
- 16.Hubert T, Wu Z, Chisholm AD, Jin Y. S6 kinase inhibits intrinsic axon regeneration capacity via AMP kinase in Caenorhabditis elegans. J. Neurosci. 2014;34:758–763. doi: 10.1523/JNEUROSCI.2886-13.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Al-Ali H, et al. The mTOR Substrate S6 Kinase 1 (S6K1) is a negative regulator of axon regeneration and a potential drug target for central nervous system injury. J. Neurosci. 2017;37:7079–7095. doi: 10.1523/JNEUROSCI.0931-17.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem. Soc. Trans. 2007;35(Pt 2):231–235. doi: 10.1042/BST0350231. [DOI] [PubMed] [Google Scholar]
- 19.Zhang BY, et al. Akt-independent GSK3 inactivation downstream of PI3K signaling regulates mammalian axon regeneration. Biochem. Biophys. Res. Commun. 2014;443:743–748. doi: 10.1016/j.bbrc.2013.12.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr. Opin. Cell Biol. 2017;45:62–71. doi: 10.1016/j.ceb.2017.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Godena VK, Ning K. Phosphatase and tensin homologue: a therapeutic target for SMA. Signal Transduct. Target. Ther. 2017;2:17038. doi: 10.1038/sigtrans.2017.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Song MS, et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell. 2011;144:187–199. doi: 10.1016/j.cell.2010.12.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Shen WH, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157–170. doi: 10.1016/j.cell.2006.11.042. [DOI] [PubMed] [Google Scholar]
- 24.Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev. Cell. 2007;12:957–971. doi: 10.1016/j.devcel.2007.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Patel S, et al. Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol. Cell. Biol. 2008;28:6314–6328. doi: 10.1128/MCB.00763-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Easton RM, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol. Cell. Biol. 2005;25:1869–1878. doi: 10.1128/MCB.25.5.1869-1878.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hu Y, et al. Differential effects of unfolded protein response pathways on axon injury-induced death of retinal ganglion cells. Neuron. 2012;73:445–452. doi: 10.1016/j.neuron.2011.11.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Petrs-Silva H, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 2011;19:293–301. doi: 10.1038/mt.2010.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wang LN, et al. Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J. Integr. Med. 2014;12:20–34. doi: 10.1016/S2095-4964(14)60003-0. [DOI] [PubMed] [Google Scholar]
- 30.Zhang YH, et al. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. J. Integr. Med. 2014;12:483–494. doi: 10.1016/S2095-4964(14)60057-1. [DOI] [PubMed] [Google Scholar]
- 31.Kwong JM, Caprioli J, Piri N. RNA binding protein with multiple splicing: a new marker for retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2010;51:1052–1058. doi: 10.1167/iovs.09-4098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Rodriguez AR, de Sevilla Muller LP, Brecha NC. The RNA binding protein RBPMS is a selective marker of ganglion cells in the mammalian retina. J. Comp. Neurol. 2014;522:1411–1443. doi: 10.1002/cne.23521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Leon S, Yin Y, Nguyen J, Irwin N, Benowitz LI. Lens injury stimulates axon regeneration in the mature rat optic nerve. J. Neurosci. 2000;20:4615–4626. doi: 10.1523/JNEUROSCI.20-12-04615.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.